Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.26 -4.34%

-$0.11 today

Market cap
$426.53M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 2.16M

Average 3.07M

OVID Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Ovid Therapeutics Inc.NASDAQ: OVID

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Over 3 fiscal years it narrowed by 4.1 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
95.9%-4.1 pp YoY
LTMMar 2026
99.5%-0.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-4.1 pp——
3 years-4.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
95.9%
Year-over-year change
-4.1pp

Gross Margin vs competitors

How OVID compares with its peers on the latest reported figures

  • OVID's LTM Mar 2026 gross margin of 99.5% is the highest of the 8 companies compared; the peer median is 84.0%.
  • Its year-over-year change of -0.5 pp is the 3rd highest of 7, against a peer median of -2.9 pp.
  • Over three fiscal years its change of -4.1 pp compares with a peer median of +0.0 pp.
OVID Competitors Peer median
Gross Margin for OVID and competitors
Company Period LTM level YoY 3-year change
OVIDOvid Therapeutics Inc.LTM Mar 202699.5% -0.5 pp-4.1 pp
WVEWave Life Sciences Ltd.LTM Mar 202693.8% -4.1 pp-20.7 pp
MGTXMeiraGTx Holdings plcLTM Mar 202691.6% +64.6 pp-6.0 pp
STOKStoke Therapeutics, Inc.LTM Mar 202690.4% -9.1 pp+0.0 pp
TSHATaysha Gene Therapies, Inc.LTM Jun 202684.0% -16.0 pp+99.4 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
ABEOAbeona Therapeutics Inc.LTM Mar 202651.9% —+5.5 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-86.7% +2.3 pp+136.3 pp
NGNENeurogene Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding OVID) 84.0%-2.9 pp+0.0 pp

Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue208.38M1.5M392K566K7.25M
Cost of Revenue0000300K
Gross Profit208.38M1.5M392K566K6.95M
Gross Margin100.0%100.0%100.0%100.0%95.9%
Research & Development46.94M24.62M28.59M36.77M25.58M
Selling, General & Admin37.23M32.43M29.59M25.68M24.11M
Operating Expenses84.17M57.05M59.67M62.45M49.39M
Depreciation & Amortization237.08K1.38M568K613K300K
EBITDA124.45M(54.17M)(57.01M)(57.77M)(17.11M)
EBITDA Margin59.7%-3604.5%-14544.1%-10207.1%-236.0%
Operating Income124.21M(55.55M)(59.28M)(61.89M)(42.44M)
Operating Margin59.6%-3696.4%-15122.7%-10933.7%-585.2%
Interest Income004.9M3.9M0
Interest Expense00000
Other Income / Expenses(45.69K)1.38M6.94M35.45M25.03M
Income Before Tax124.16M(54.17M)(52.34M)(26.43M)(17.41M)
Pre-Tax Margin59.6%-3604.7%-13351.8%-4670.1%-240.1%
Income Tax Expense1.33M0000
Net Income122.83M(54.17M)(52.34M)(26.43M)(17.41M)
Net Margin58.9%-3604.7%-13351.8%-4670.1%-240.1%
EPS (Basic)1.78(0.77)(0.74)(0.37)(0.24)
EPS (Diluted)1.76(0.77)(0.74)(0.37)(0.24)
Weighted Avg Shares67.48M70.43M70.58M70.91M73.74M
Weighted Avg Shares (Diluted)68.07M70.43M70.58M70.91M73.74M

Ovid Therapeutics Inc.

NASDAQ:OVID

Intrinsic Alpha fair value

Locked

Current Price

$2.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.